Scientific Presentations

March 2026

8th International Congress on Controversies in Fibromyalgia Oral Presentations

Phase 3 RESILIENT Study Post Hoc Analysis
March 2026

2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting

January 2026

Non-Opioid Pain Therapeutics Summit, Boston MA / 27-29 Jan 2026

October 2025

American College of Rheumatology Convergence Conference 2025, Chicago: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia

October 2025

World Vaccine Conference 2025, Amsterdam: Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine

October 2025

61st Annual Congress of the Japan Society for Transplantation

September 2025

PainWeek 2025 — Randomized, double-blind, placebo-controlled confirmatory Phase 3 trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in fibromyalgia

September 2025

PainWeek 2025 — Sublingual cyclobenzaprine (TNX-102 SL) for fibromyalgia: efficacy and safety in two randomized placebo-controlled trials

September 2025

PainWeek 2025 — TNX-102 SL, cyclobenzaprine HCl sublingual tablets, demonstrates pain reduction and favorable tolerability in patients with fibromyalgia

September 2025

PainWeek 2025 — Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl (TNX-102 SL): comparison to simulations of oral immediate-release CBP

July 2025

World Congress on Vaccines 2025 — TNX-801, a Single-Dose Live Vaccine Platform for Mpox and Other Emerging Viral Diseases: Safety, Immunogenicity, and Efficacy

June 2025

EULAR 2025: Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Nonrestorative Sleep and Provides Sustained Pain Reduction

April 2025

AACR 2025: TFF2-mediated CXCR4 partial agonism outperforms CXCR4 antagonism in reducing murine gastric cancer by suppressing PMN-MDSC generation

April 2025

AAPM PainConnect 2025: Sublingual Cyclobenzaprine (TNX-102 SL) for Fibromyalgia: Efficacy and Safety in Two Randomized, Placebo-Controlled Trials

March 2025

UT Southwestern Microbiology Department Seminar 2025: Resurrecting Dr. Edward Jenner’s 1796 Horsepox Vaccine to Protect Against Mpox and Smallpox

March 2025

Controversies in Fibromyalgia 2025: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Treatment of Fibromyalgia at Bedtime to Target Non-Restorative Sleep Showed Durable Pain Reduction in Two Double-Blind Randomized Phase 3 Studies

November 2024

American College of Pheumatology Convergence 2024: Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia

October 2024

World Vaccine Congress: TNX-801 MPOX — A live, attenuated, minimally replicative, MPOX vaccine candidate

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: The Importance of in Vitro Discriminatory Tests in the Development of a Sublingual Dosage Form of TNX-102 SL (Cyclobenzaprine HCI) Tablets

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: Pharmacokinetic Properties of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride

September 2024

Symposium to Honor Prof. David Evans: Using Synthetic Biology to Battle Mpox

August 2024

MHSRS 2024: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing

August 2024

MHSRS 2024: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD

August 2024

MHSRS 2024: Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL

August 2024

MHSRS 2024: TNX-102 SL for Fibromyalgia

August 2024

IASP 2024: Targeting Fibromyalgia Non-Restorative Sleep with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl): Results of the Positive Phase 3 RESILIENT Trial Consistent with Syndromal Improvement

June 2024

Vaccine Congress 2024: Horsepox: A Live Virus, Single-Dose Vaccine Platform

June 2024

AHS 2024: American Headache Society Consensus Statement and Other Recommendations: How Many Practitioners Comply With the Recommendations?

June 2024

EULAR 2024: Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial

June 2024

American Transplant Congress 2024: Combined blockade of CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunityand prolongs survival in cynomolgus cardiac allografts

June 2024

ATC 2024: Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade –Based Immunosuppression

June 2024

ATC 2024: Delayed Immune Tolerance for Cardiac Allografts in Nonhuman Primates by Targeting CD154, CD2, and CD28 Costimulation Pathways

June 2024

ASCP Annual Meeting 2024: Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) on Mood and Anxiety Symptoms in Fibromyalgia

May 2024

ASCP Annual Meeting 2024: Fibromyalgia-Type Long COVID

May 2024

ASCP Annual Meeting 2024: Acute Stress Disorder

April 2024

AACR Annual Meeting 2024: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

April 2024

World Vaccine Congress 2024: Attenuation of the Horsepox Virus Platform as a Vaccine for Mpox/Smallpox (TNX-801)

March 2024

American Chemistry Society (ACS) Spring 2024: Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations

March 2024

Controversies in Fibromyalgia 2024: Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled RESILIENT Trial

March 2024

Controversies in Fibromyalgia: Tonmya* (TNX-102 SL) in Development for the Management of Fibromyalgia

October 2023

 Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in a Preclinical Model

October 2023

Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade–Based Immunosuppression

October 2023

WVC Europe: A Novel Mpox Vaccine (Horsepox Platform) to Enhance Preparedness and Global Vaccine Equity

October 2023

FPWR: A planned phase 2, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of TNX-2900 for the treatment of patients with Prader-Willi syndrome

September 2023

CICON: mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated CT26.WT Subcutaneous and CT26-Luciferase Orthotopic Syngeneic Colorectal Cancer Models by Targeting MDSCs in BALB/C Mice

September 2023

IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons, the Expression of which is Dramatically Increased by Inflammation

September 2023

IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons: Expression Increased by Inflammation

June 2023

ATC: aCD154mAb (TNX-1500) Alone, or in Combination with Rapamycin, MMF, or aCD28mAb (VEL-101) Prolongs Cynomolgus Cardiac Allograft Survival

June 2023

ATC: Fc-Modified Anti-CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications

June 2023

ATC: Efficacy of CD154 Blockade with TNX-1500 to Prevent Heart Allograft Immune Injury

June 2023

ASCP 2023: A Randomized Placebo-Controlled Multicenter Trial of Monotherapy with TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for Treatment of Major Depressive Disorder (MDD)

April 2023

AACR: MDSC-targeted TFF2-MSA Synergizes with PD-1 Blockade Therapy in Advanced Gastric Cancer Models

April 2023

AACR: MDSC-Targeted mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated MC38 and CT26.wt Murine Colorectal Cancer Models

April 2023

TNX-801: A Novel Mpox Vaccine: Live, Replicating, Attenuated Orthopoxvirus (Horsepox) Vaccine

April 2023

The Development of Horsepox Virus as a Vaccine Platform: Evaluation of TNX-1800 as a SARS-CoV-2 Vaccine

March 2023

The 5th International Congress on Controversies in Fibromyalgia

March 2023

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Randomized, Placebo-Controlled RELIEF Trial

March 2023

TNX-2900 — Rare Disease Summit, Philadelphia, 23-March-2023

March 2023

mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in an Anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs

February 2023

TNXP Presentation for BIO and Solve ME Event

January 2023

Primary vs Secondary Sex Hormones and Migraine

January 2023

Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy

December 2022

Live Virus Smallpox and Monkeypox Vaccine

November 2022

Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies

November 2022

In Vitro Impact of Oxytocin on Human Sensory Neurons

September 2022

Retrospective Observational Database Study of Patients with Long COVID with Multi-Site Pain, Fatigue, and Insomnia: A Real-World Analysis of Symptomatology and Opioid Use

September 2022

Monotherapy with TNX-1500, an Fc-modified Anti-CD154 mAb, Prolongs Cardiac Allograft Survival in Cynomolgus Monkeys

September 2022

Long-term (>1 year) Rejection/TMA Free Survival of Kidney Xenografts with Triple Xenoantigen Knockout and Multiple Human Transgenes in Nonhuman Primates

September 2022

Long-term Rejection Free Renal Allograft Survival with Fc-modified Anti-CD154 Antibody Monotherapy in Nonhuman Primates

June 2022

TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival 

June 2022

Long Term Rejection Free Renal Allograft Survival with Fc Modified Anti CD154 Antibody Monotherapy in Nonhuman Primates

June 2022

Novel Targetable Pathways in Costimulation Pathway Blockade

June 2022

The Virus-host Interface: A Treasure Trove of Novel Antiviral Targets

June 2022

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox

November 2021

TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder

November 2021

TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial

July 2020

Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)

June 2021

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

June 2021

Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD

June 2020

Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

January 2020

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*

November 2019

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

May 2019

Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP

November 2018

Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD

November 2018

Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

August 2017

Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response

August 2017

Efficacy and Safety of a Low Dose, Bedtime, Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL#) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301)

August 2018

Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies

May 2018

Including Suicidal Individuals in Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL, a Novel Sublingual Formulation of Cyclobenzaprine Hypothesized to Address PTSD through Improvement in Sleep Quality

June 2017

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

May 2017

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

May 2017

Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response

December 2016

The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX – 102 SL in the Treatment of Military-Related PTSD

November 2016

Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial

November 2016

The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD

October 2016

A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD: Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Gregory Sullivan – Results of the Phase 2 “AtEase Study” in Military-Related PTSD

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Thomas A. Mellman – Focus on Sleep and PTSD Treatment Populations

August 2016

The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

June 2016

TNX-102 SL for the Treatment of Fibromyalgia — Comparison of 30% Pain Respondent Analysis with Omeract Draft Composite Responder Endpoint Analyses

June 2016

A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

May 2016

A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

March 2016

Rapid Sublingual Absorption of Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM) Presentation Number: LB-026

November 2015

Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)

November 2015

Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)

November 2015

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study

November 2015

An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD

November 2015

Comparative Neuropharmacology of Therapeutic Agents Targeting Posttraumatic Stress Disorder

June 2015

Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD)

June 2015

TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement

June 2015

TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization

August 2015

The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models

August 2015

The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

August 2015

(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache

November 2013

Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications…

LOAD MORE